Profile Details

Create Project

★★★★★

☆☆☆☆☆

USD 120 /hr

★★★★★

☆☆☆☆☆

Hire Renu J.

Canada

USD 120 /hr

Clinical Trial Manager & PhD Scientist | Protocols • Literature Reviews • Regulatory Writing • Molecular Biology Expert

Profile Summary

I am a PhD-trained scientist in Epigenetics (University of Toronto) with a Master’s in Molecular Biology and extensive experience working across clinical operations, CRO environments, and academic research. I currently teach clinical research and scientific subjects at AAPS and support life science teams with high-quality, evidence-based deliverables. My expertise spans clinical trials, scientific writing, and molecular biology, allowing me to translate complex concepts into clear, accurate, and publication-ready content. I bring the combined perspective of a bench scientist, clinical trial manager, and regulatory contributor, ensuring that all documents meet scientific and operational standards. I support biotech, pharma, health-tech, and academic groups needing reliable scientific consulting, literature synthesis, and clinical trial documentation.

Subject Matter Expertise

• ★ IRB Applications
• ★ Clinical Trial Design
• ★ Pharmacovigilance/Drug Safety Monitoring
• ☆ Drug Discovery
• ☆ High Throughput Screening (HTS)
• ☆ Phenotypic Assays
• ☆ Drug Design
• ☆ Clinical Trials
• ☆ Patient Recruitment
• ☆ Clinical Trials Data Analysis
• ☆ Human Biology
• ☆ Regulatory Affairs
• ☆ Pharmaceutical Management

Services

• Writing
• Research
• Consulting
• Data & AI
• Product Development

Writing Clinical Trial Documentation, Medical Writing, Non-Medical Regulatory Writing, Technical Writing, Translation

Research User Research, Scientific and Technical Research, Systematic Literature Review

Consulting Healthcare Consulting, Scientific and Technical Consulting, Regulatory Consulting, Manufacturing Consulting

Data & AI Predictive Modeling, Data Mining, Data Processing, Data Insights

Product Development Formulation, Quality Assurance & Control (QA/QC), Product Compliance

Work Experience

Project Manager

SickKids

- Present

Project Manager

ACCESS, The Hospital for Sick Children (SickKids)

July 2025 - Present

Lecturer, Senior Lecturer

Academy of Applied Pharmaceutical Sciences

April 2025 - Present

Study Director/Research Supervisor

Kingfisher International

September 2020 - July 2025

Global Clinical Trial Manager

Lunenfeld-Tanenbaum Research Institute, Sinai Health

June 2015 - September 2020

Education

DPhil (PhD) Epigenetics

University of Toronto

September 2015 - June 2020

Masters of Science

Ryerson University

September 2012 - June 2015

Honors Bachelors of Science

University of Toronto

September 2007 - June 2011

Certifications

• Certification details not provided.

Publications

JOURNAL ARTICLE

Multilevel interrogation of H3.3 reveals a primordial role in transcription regulation @article{Jeyapala,2023,title = {Multilevel interrogation of H3.3 reveals a primordial role in transcription regulation},journal = {Epigenetics and Chromatin},year = {2023},volume = {16},number = {1},author = {Nabeel-Shah, S. and Garg, J. and Ashraf, K. and Jeyapala, R. and Lee, H. and Petrova, A. and Burns, J.D. and Pu, S. and Zhang, Z. and Greenblatt, J.F. and Pearlman, R.E. and Lambert, J.-P. and Fillingham, J.}} . Epigenetics and Chromatin.

Combining CAPRA-S With Tumor IDC/C Features Improves the Prognostication of Biochemical Recurrence in Prostate Cancer Patients @article{Jeyapala,2022,title = {Combining CAPRA-S With Tumor IDC/C Features Improves the Prognostication of Biochemical Recurrence in Prostate Cancer Patients},journal = {Clinical Genitourinary Cancer},year = {2022},volume = {20},number = {3},pages = {e217-e226},author = {Jeyapala, R. and Kamdar, S. and Olkhov-Mitsel, E. and Zlotta, A. and Fleshner, N. and Visakorpi, T. and van der Kwast, T. and Bapat, B.}} . Clinical Genitourinary Cancer.

Investigating Urinary Circular RNA Biomarkers for Improved Detection of Renal Cell Carcinoma @article{Jeyapala,2022,title = {Investigating Urinary Circular RNA Biomarkers for Improved Detection of Renal Cell Carcinoma},journal = {Frontiers in Oncology},year = {2022},volume = {11},author = {Peter, M.R. and Zhao, F. and Jeyapala, R. and Kamdar, S. and Xu, W. and Hawkins, C. and Evans, A.J. and Fleshner, N.E. and Finelli, A. and Bapat, B.}} . Frontiers in Oncology.

Temporal stability and prognostic biomarker potential of the prostate cancer urine mirna transcriptome @article{Jeyapala,2021,title = {Temporal stability and prognostic biomarker potential of the prostate cancer urine mirna transcriptome},journal = {Journal of the National Cancer Institute},year = {2021},volume = {112},number = {3},pages = {247-255},author = {Jeon, J. and Olkhov-Mitsel, E. and Xie, H. and Yao, C.Q. and Zhao, F. and Jahangiri, S. and Cuizon, C. and Scarcello, S. and Jeyapala, R. and Watson, J.D. and Fraser, M. and Ray, J. and Commisso, K. and Loblaw, A. and Fleshner, N.E. and Bristow, R.G. and Downes, M. and Vesprini, D. and Liu, S. and Bapat, B. and Boutros, P.C.}} . Journal of the National Cancer Institute.

Methylation Markers in Prostate Biopsies Are Prognosticators for Late Biochemical Recurrence and Therapy after Surgery in Prostate Cancer Patients @article{Jeyapala,2020,title = {Methylation Markers in Prostate Biopsies Are Prognosticators for Late Biochemical Recurrence and Therapy after Surgery in Prostate Cancer Patients},journal = {Journal of Molecular Diagnostics},year = {2020},volume = {22},number = {1},pages = {30-39},author = {Savio, A.J. and Kamdar, S. and Jeyapala, R. and Olkhov-Mitsel, E. and Cuizon, C. and Finelli, A. and Zlotta, A.R. and Toi, A. and Fleshner, N.E. and van der Kwast, T. and Bapat, B.}} . Journal of Molecular Diagnostics.

An integrative DNA methylation model for improved prognostication of postsurgery recurrence and therapy in prostate cancer patients @article{Jeyapala,2020,title = {An integrative DNA methylation model for improved prognostication of postsurgery recurrence and therapy in prostate cancer patients},journal = {Urologic Oncology Seminars and Original Investigations},year = {2020},volume = {38},number = {2},pages = {39-39.e9},author = {Jeyapala, R. and Kamdar, S. and Olkhov-Mitsel, E. and Savio, A.J. and Zhao, F. and Cuizon, C. and Liu, R.S. and Zlotta, A. and Fleshner, N. and van der Kwast, T. and Bapat, B.}} . Urologic Oncology Seminars and Original Investigations.

Urinary biomarkers in prostate cancer: To the miRnome and beyond @article{Jeyapala,2020,title = {Urinary biomarkers in prostate cancer: To the miRnome and beyond},journal = {Translational Andrology and Urology},year = {2020},volume = {9},number = {2},pages = {843-845},author = {Hoey, C. and Jeyapala, R. and Boutros, P.C. and Bapat, B. and Liu, S.K.}} . Translational Andrology and Urology.

GBX2 Methylation Is a Novel Prognostic Biomarker and Improves Prediction of Biochemical Recurrence Among Patients with Prostate Cancer Negative for Intraductal Carcinoma and Cribriform Architecture @article{Jeyapala,2019,title = {GBX2 Methylation Is a Novel Prognostic Biomarker and Improves Prediction of Biochemical Recurrence Among Patients with Prostate Cancer Negative for Intraductal Carcinoma and Cribriform Architecture},journal = {European Urology Oncology},year = {2019},volume = {2},number = {3},pages = {231-238},author = {Jeyapala, R. and Savio, A.J. and Olkhov-Mitsel, E. and Kamdar, S. and Zhao, F. and Cuizon, C. and Liu, R.S.C. and Zlotta, A. and Fleshner, N. and van der Kwast, T. and Bapat, B.}} . European Urology Oncology.

Assessment of Serum microRNA Biomarkers to Predict Reclassification of Prostate Cancer in Patients on Active Surveillance @article{Jeyapala,2018,title = {Assessment of Serum microRNA Biomarkers to Predict Reclassification of Prostate Cancer in Patients on Active Surveillance},journal = {Journal of Urology},year = {2018},volume = {199},number = {6},pages = {1475-1481},author = {Liu, R.S.C. and Olkhov-Mitsel, E. and Jeyapala, R. and Zhao, F. and Commisso, K. and Klotz, L. and Loblaw, A. and Liu, S.K. and Vesprini, D. and Fleshner, N.E. and Bapat, B.}} . Journal of Urology.

A urine-based DNA methylation assay, ProCUrE, to identify clinically significant prostate cancer @article{Jeyapala,2018,title = {A urine-based DNA methylation assay, ProCUrE, to identify clinically significant prostate cancer},journal = {Clinical Epigenetics},year = {2018},volume = {10},number = {1},author = {Zhao, F. and Olkhov-Mitsel, E. and Kamdar, S. and Jeyapala, R. and Garcia, J. and Hurst, R. and Hanna, M.Y. and Mills, R. and Tuzova, A.V. and O{'}Reilly, E. and Kelly, S. and Cooper, C. and Brewer, D. and Perry, A.S. and Clark, J. and Fleshner, N. and Bapat, B.}} . Clinical Epigenetics.

Re: Urinary DNA Methylation Biomarkers for Noninvasive Prediction of Aggressive Disease in Patients with Prostate Cancer on Active Surveillance: F. Zhao, E. Olkhov-Mitsel, T. van der Kwast, J. Sykes, D. Zdravic, V. Venkateswaran, A. R. Zlotta, A. Loblaw, N. E. Fleshner, L. Klotz, D. Vesprini and B. Bapat J Urol 2017; 197: 335–341. @article{Jeyapala,2018,title = {Re: Urinary DNA Methylation Biomarkers for Noninvasive Prediction of Aggressive Disease in Patients with Prostate Cancer on Active Surveillance: F. Zhao, E. Olkhov-Mitsel, T. van der Kwast, J. Sykes, D. Zdravic, V. Venkateswaran, A. R. Zlotta, A. Loblaw, N. E. Fleshner, L. Klotz, D. Vesprini and B. Bapat J Urol 2017; 197: 335?341.},journal = {Journal of Urology},year = {2018},volume = {199},number = {5},pages = {1354-1355},author = {Zhao, F. and Jeyapala, R. and Olkhov-Mitsel, E. and Vesprini, D. and Fleshner, N.E. and Bapat, B.}} . Journal of Urology.